𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia

✍ Scribed by Rebekah L. Browning; Susan M. Geyer; Amy J. Johnson; Diane F. Jelinek; Renee C. Tschumper; Timothy G. Call; Tait D. Shanafelt; Clive S. Zent; Nancy D. Bone; Gordon W. Dewald; Thomas S. Lin; Nyla A. Heerema; Michael R. Grever; Neil E. Kay; John C. Byrd; David M. Lucas

Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
208 KB
Volume
31
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

✦ Synopsis

TCL-1 expression is variable in CLL, and no study has examined its association with treatment response. We measured TCL-1 protein in CLL cells from 51 patients who then received pentostatin, cyclophosphamide, and rituximab. TCL-1 expression did not correlate with any pre-treatment characteristics. Lower TCL-1 levels were associated with higher probability of attaining flow cytometry-negative status post-treatment (52% versus 17%, p=0.046). Trends toward improved complete remission rate (49% versus 19%, p=0.064) and progression-free survival (medians: 33 versus 20 months, p=0.199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted.

πŸ“œ SIMILAR VOLUMES

Calorimetric study as a potential test f
Calorimetric study as a potential test for choosing treatment of B-cell chronic lymphocytic leukemia
✍ Malgorzata Rogalinska; Pawel Goralski; Katarzyna Wozniak; Jolanta D. Bednarek; J πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 346 KB

Differential scanning calorimetry (DSC) and complementary techniques were utilized to evaluate the sensitivity of B-cell chronic lymphocytic leukemia (B-CLL) cell samples in vitro exposed to cladribine or fludarabine in combination with mafosfamide. Mafosfamide, the active in vitro form of cyclophos

Investigation of an NQO1 polymorphism as
Investigation of an NQO1 polymorphism as a possible risk and prognostic factor for chronic lymphocytic leukemia
✍ Asher Begleiter; Donna Hewitt; Spencer B. Gibson; James B. Johnston πŸ“‚ Article πŸ“… 2009 πŸ› Elsevier Science 🌐 English βš– 395 KB

NAD(P)H:quinoneoxidoreductase 1 (NQO1) inhibits some cancers and increases p53 and apoptosis in cells. Due to an inactivating polymorphism, 10% of humans have no NQO1 activity. A case:control study suggested that chronic lymphocytic leukemia (CLL) patients may have an increased incidence of the NQO1

CD38 as a prognostic factor in B cell ch
CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): Comparison of three approaches to analyze its expression
✍ Joke G. Boonstra; Kirsten van Lom; Anton W. Langerak; Wilfried J. Graveland; Pet πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 411 KB πŸ‘ 1 views

## Abstract ## Background: Increased CD38 expression by leukemic cells has been suggested as an adverse prognostic factor in B‐CLL. Several approaches have been proposed to quantify its level of expression by flow cytometry. ## Methods: We compared the use of (i) the percentage of CD38 positive